Search results for "Napabucasin"

showing 2 items of 2 documents

CanStem303C trial: A phase III study of napabucasin (BBI-608) in combination with 5-fluorouracil (5-FU), leucovorin, irinotecan (FOLFIRI) in adult pa…

2017

TPS3619 Background: Cancer stem cells are considered to be fundamentally important for resistance to therapy, recurrence and metastasis. Napabucasin is a first-in-class cancer stemness inhibitor in development identified by its ability to inhibit STAT3-driven gene transcription and spherogenesis of cancer stem cells (Li et al, PNAS 112(6):1839, 2015). Preclinically, napabucasin sensitizes cancer cells to chemotherapeutics, including 5-FU and irinotecan. Encouraging anticancer activity in advanced CRC was observed in a phase Ib/II (Bendell et al, GI ASCO 2017) study of 63 pts with disease control rate (DCR) of 93% (28/30) and overall response rate (ORR) of 33% (10/30) in FOLFIRI-naïve pts w…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtybusiness.industryColorectal cancerCancermedicine.diseaseMetastasisIrinotecan03 medical and health sciences030104 developmental biology0302 clinical medicineOncologyCancer stem cellFluorouracil030220 oncology & carcinogenesisInternal medicinemedicineFOLFIRIbusinessNapabucasinmedicine.drugJournal of Clinical Oncology
researchProduct

O-7 FOLFIRI ± napabucasin in patients with previously treated metastatic colorectal cancer: Overall survival results from the phase 3 CanStem303C stu…

2021

Oncologymedicine.medical_specialtyColorectal cancerbusiness.industryHematologymedicine.diseaseOncologyInternal medicineOverall survivalmedicineFOLFIRIIn patientPreviously treatedbusinessNapabucasinAnnals of Oncology
researchProduct